MHRA Approval for Formal Human Trials to Start

The University of Liverpool, as Sponsor of APPA’s clinical program, has received clinical trial authorisation (CTA) from the MHRA (Medicines & Healthcare Products Regulatory Agency) to commence the Phase I clinical trial. The ongoing clinical program will test AKLRD’s lead candidate, APPA, as a potential new treatment for osteoarthritis. David Sharples, Chief Executive Officer at […]

Read More

Under-exploited plants offer untold economic promise

A recent article in Nature by Ameenah Gurib Fakim, President of Mauritius and former Professor of Organic Chemistry, about the abundance of commercially available drugs that have their origins in plants. “Artemisinin, ginkgolides, quinine, reserpine, scopolamine, paclitaxel. What do these molecules have in common? They are all extracted from plants and transformed into useful drugs, […]

Read More

AKLRD and APPA in the Press

Recently there have been various press reports on AKLRD’s collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively.     Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development […]

Read More

Liverpool University Press Release

Clinical trial for new innovative Osteoarthritis drug The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people*, and is […]

Read More

Summary of Effects of APPA on Neutrophils

AKLRD, in collaboration with the University of Liverpool, were accepted for a presentation at the 2016 OARSI (Osteoarthritis Research Society International) Congress Summary of Effects of APPA on Human Neutrophils Function APPA is a synergistic combination of 2 synthetic anti-inflammatory molecules. APPA has shown efficacy in several animal models of osteoarthritis, decreasing pain and meniscal […]

Read More

APPA has completed required preclinical studies

We believe APPA is now ready to apply for regulatory approval to start formal human trials now that required preclinical toxicology studies have been completed. There is a considerable body of evidence behind the efficacy, safety, tolerability and mode of action of APPA. Consistent with data in the public domain, the studies undertaken indicate that […]

Read More